2 results
Approved WMOCompleted
To evaluate the safety and efficacy of subcutaneousbelimumab (GSK1550188) and intravenous rituximab coadministrationin subjects with primary Sjögren*s syndrome.
Approved WMOCompleted
The primary objective of this study is to evaluate the effect (reduction of bleeding on probing) after mechanical debridement alone or treatment with delmopinol or chlorhexidine mouth rinse as an adjunct to mechanical debridement around implants…